System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Gilles Lemesle is an expert in Cardiology at Centre Hospitalier Universitaire de Lille (France). As of October 2026, ScienceLeadR ranks Gilles Lemesle in the top 1% of experts worldwide for Myocardial Ischemia, Coronary Disease and Arteriosclerosis. Gilles Lemesle has authored 299 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 6 of them ongoing. SLR score: 1,269 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Gilles Lemesle Centre Hospitalier Universitaire de Lille France
1 269 ScienceLeadR Reputation 1269

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Biostatistics - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Institut Pasteur

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 299

Citations

Citations: 6 348 1st author: 65 Last author: 28 Unique author: 3

Main journals

Arch Cardiovasc Dis 29
Circulation 20
Cardiovasc Revasc Med 18
Am J Cardiol 16
Eur Heart J 15

Best Journals

Circulation 9
N Engl J Med 8
Eur Heart J 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
[LDL-c and residual cardiovascular risk in patients with coronary artery disease].
PMID 42934030 — cholesterol, ldl, coronary artery disease, angiography, arteries, cardiology, therapeutics, blood vessels		Ann Cardiol Angeiol (Paris)20260
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
PMID 42670965 — safety, hemorrhage, ischemic stroke, stroke, myocardial infarction, acute coronary syndrome, therapeutics		N Engl J Med Top journal20264
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PMID 42669300 — myocardial infarction, heart failure, heart, therapeutics		Lancet Top journal20262
Unsupervised clustering identifies distinct phenotypes in acute myocardial infarction: insights from the FAST-MI 2015 registry.
PMID 42689178 — registries, mortality, myocardial infarction, phenotype, classification, acute coronary syndrome, cluster analysis, precision medicine, prognosis		Front Artif Intell20260
Comparison of Local Investigator and Core Laboratory Assessment of Cardiac MRI-derived Left Ventricular Ejection Fraction in the MyocarditIRM Study.
PMID 42560173 — laboratories		Radiol Cardiothorac Imaging20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 13
Phase 3 11
Phase 4 3
Phase 1/Phase 2 2
Phase 2 1

By status:

Completed 18
Recruiting 6
Active not recruiting 2
Unknown 2
Suspended 1
Terminated 1

By type:

Interventional 23
Observational 7

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 1
multicentric5to9 1
multicentricup10 13

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Rituximab in patients with ST elevation myocardial infarction A phase 2 placebo controlled randomized clinical trial
2022-501893-21-00 — myocardial infarction, st elevation myocardial infarction, rituximab		Phase 2Recruiting2022
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction
2024-511882-13-01 — myocardial infarction, heart failure, echocardiography, therapeutics		Phase 3Active not recruiting2024
A Trial to Test How AZD0780 Affects Serious Heart Stroke or Vascular Problems in Patients with Heart Stroke or Vascular Disease or at High Risk for Such Issues
2025-520519-14-00 — stroke, heart, cardiovascular diseases, vascular diseases		Phase 3Recruiting2025
A Phase 1b 2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ AK1967) in Critical Cardiovascular Care
NCT06832722 — safety, shock, cardiogenic, multiple chronic conditions, peptide hydrolases, antibodies, monoclonal, pharmacokinetics		Phase 1/Phase 2Recruiting2025
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality Rehospitalization Left Ventricular Ejection Fraction and Renal Function
NCT05879276 — sodium-glucose transporter 2 inhibitors, mortality, shock, cardiogenic, heart failure, heart, therapeutics, prognosis		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS